<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Insulin-induced hypoglycemia test protocol
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Insulin-induced hypoglycemia test protocol
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Insulin-induced hypoglycemia test protocol
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hershel Raff, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of adrenal insufficiency usually can be made by the findings of low morning serum cortisol and a subnormal response to synthetic corticotropin (ACTH [1-24]) [
         <a href="#rid1">
          1,2
         </a>
         ]. In very rare circumstances, however, other tests, such as insulin-induced hypoglycemia, can be utilized to evaluate the pituitary-adrenal response to stress, particularly when recent onset of ACTH deficiency is suspected as the cause of adrenal insufficiency. Compared with other tests for the diagnosis of adrenal insufficiency, the insulin-induced hypoglycemia test is more difficult to perform, poses greater risk, and is much more expensive. As a result, it is infrequently performed in clinical practice for the assessment of pituitary-adrenal function.
        </p>
        <p>
         Details of insulin-induced hypoglycemia test (also referred to as the "insulin tolerance test" or "ITT") in adults will be reviewed here. Additional information on the diagnosis of adrenal insufficiency, the evaluation of patients after pituitary surgery, and diagnostic testing for adult growth hormone deficiency is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">
          "Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'First evaluation post-discharge'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6641.html" rel="external">
          "Growth hormone deficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4255826348">
         <span class="h1">
          CLINICAL USES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for the insulin-induced hypoglycemia test (insulin tolerance test [ITT]) is that hypoglycemia induced by insulin administration is a sufficient stress to stimulate corticotropin-releasing hormone (CRH), corticotropin (ACTH), and therefore cortisol secretion. One advantage of this test is that the results correlate relatively well with the serum cortisol response to surgical stress. Although this is a valid test of the hypothalamic-pituitary-adrenal response to stress, in most settings, the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         provides nearly the same information, is much less difficult and less expensive to perform, and is without risk to the patient. Nonetheless, the ITT may have utility in specific clinical settings. (See
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1335890573">
         <span class="h2">
          Recent pituitary surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recent pituitary surgery is the main clinical scenario in which the
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         has limited diagnostic utility. If ACTH deficiency occurs as a result of transsphenoidal surgery, the cortisol response to exogenous ACTH stimulation may be normal in the first month or two after surgery. An abnormal response does not evolve until the volume of the adrenal cortex has decreased significantly. In this setting, the ITT may be a better test to diagnose ACTH deficiency because the ACTH response to hypoglycemia may be lost in the early postoperative period [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">
          "Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'First evaluation post-discharge'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults", section on 'Recent ACTH deficiency'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ITT versus other dynamic tests
         </strong>
         – Available data suggest that ACTH stimulation tests are not ideal to test for adrenal insufficiency in the immediate postoperative period and that at one month after surgery, ACTH stimulation tests may under- or overdiagnose adrenal insufficiency depending on the dose of synthetic corticotropin utilized [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the overnight
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         test may also be used to diagnose adrenal insufficiency in the postoperative setting [
         <a href="#rid6">
          6
         </a>
         ], this test is available in few medical centers. The overnight metyrapone test, when performed six weeks after transsphenoidal surgery, correlates well with the cortisol response to insulin-induced hypoglycemia [
         <a href="#rid6">
          6
         </a>
         ]. This test confers fewer risks than the ITT and may be preferred where available. (See
         <a class="medical medical_review" href="/z/d/html/162.html" rel="external">
          "Metyrapone stimulation tests"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term predictive utility of the ITT
         </strong>
         – A normal cortisol response to the ITT is a strong predictor of intact hypothalamic-pituitary-adrenal axis function. However, an abnormal cortisol response to insulin-induced hypoglycemia in the immediate postoperative period may not predict long-term axis dysfunction. In one study of 36 patients with an abnormal response to ITT at three months after surgery, 20 patients had a normal response at 12 months [
         <a href="#rid7">
          7
         </a>
         ]. In another study, all six patients with an abnormal response to ITT in the immediate postoperative period had a normal response at three months [
         <a href="#rid3">
          3
         </a>
         ]. By contrast, very few patients with an initially normal response to insulin or ACTH progress to an abnormal function [
         <a href="#rid5">
          5,7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3421201537">
         <span class="h2">
          Growth hormone deficiency: Not recommended
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not suggest the insulin-induced hypoglycemia test for the evaluation of growth hormone deficiency. It was more commonly used in the past, but its disadvantages are that it requires constant supervision by a clinician and the symptoms of hypoglycemia can be very unpleasant for the patient. In fact, none of the tests for secondary adrenal insufficiency (ACTH or CRH stimulation; insulin-induced hypoglycemia) seem to perform well in patients with growth hormone deficiency. This issue is discussed in more detail separately [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6641.html" rel="external">
          "Growth hormone deficiency in adults", section on 'Insulin-induced hypoglycemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3290992294">
         <span class="h1">
          PRACTICAL ASPECTS
         </span>
        </p>
        <p class="headingAnchor" id="H59066208">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         This test is contraindicated in patients with coronary heart disease, cerebrovascular disease, or epilepsy; if coronary disease is suspected, appropriate evaluation must be performed before considering the insulin tolerance test (ITT). (See
         <a class="medical medical_review" href="/z/d/html/1519.html" rel="external">
          "Screening for coronary heart disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3176975583">
         <span class="h2">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient fasts for at least eight hours before the test and must remain supine during the procedure. An experienced clinician must be present at all times to monitor for complications related to hypoglycemia (chest pain, tachycardia, and/or neuroglycopenic symptoms [confusion, seizures]). A syringe containing 50 percent glucose solution should be at the bedside. An intravenous line is established, and insulin is injected intravenously. The usual dose is 0.15 units/kg of
         <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">
          regular insulin
         </a>
         , but different doses may be indicated in certain patients [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients thought to have hypopituitarism or primary adrenal insufficiency, the insulin dose is decreased to 0.1 units/kg because these conditions may be associated with decreased release of other counterregulatory hormones such as epinephrine and growth hormone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with obesity, diabetes mellitus, or suspected acromegaly or Cushing syndrome, the dose is increased to 0.2 units/kg. However, coronary disease must be ruled out before performing the test, particularly at this higher dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In premenopausal women, the test can be performed at any phase of the menstrual cycle as there are no cycle effects on the hypothalamic-pituitary-adrenal axis response to insulin-induced hypoglycemia [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Blood is obtained for bedside measurement of serum glucose and for laboratory measurement of serum glucose and cortisol levels (and for plasma corticotropin [ACTH], if indicated) immediately before insulin is injected and every 15 minutes thereafter. The final, definitive blood sample for measurement of ACTH and cortisol should be obtained 5 to 10 minutes after the patient begins to perspire or, if it can reliably be measured, when the serum glucose falls below 35 mg/dL (1.9 mmol/L). As noted, there is no clear consensus about the glucose nadir necessary for optimal test performance. While many use 35 mg/dL (1.9 mmol/L), others use 40 or 45 mg/dL (2.2 or 2.4 mmol/L) [
         <a href="#rid6">
          6,12
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Almost all patients have some degree of perspiration. If the patient does not perspire, the adequacy of the stress stimulus must remain suspect regardless of the serum glucose concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most patients also have a hyperactive precordium (but not tachycardia or hypotension, because they are supine), and feelings of hunger, drowsiness, detachment, or anxiety. The last is common and sometimes severe, and many patients find this an unpleasant experience.
        </p>
        <p>
        </p>
        <p>
         The nadir in blood glucose usually occurs 30 to 45 minutes after insulin injection. If adequate hypoglycemia is not achieved, a second similar dose of
         <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">
          regular insulin
         </a>
         should be injected intravenously. Adequate hypoglycemia should be achieved within the subsequent 30 to 45 minutes.
        </p>
        <p>
         Ideally, an automated glucose oxidase analyzer or calibrated and validated point of care device should be available at the bedside. Unfortunately, most glucose oxidase strips, whether read visually or with a glucose meter, are inaccurate at low serum glucose concentrations, tending to underestimate them, leading to premature termination of the test.
        </p>
        <p>
         Patients with primary or secondary adrenal insufficiency or longstanding diabetes mellitus have an impaired compensatory response to hypoglycemia. (See
         <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">
          "Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therefore, the test should be stopped when the serum glucose concentration decreases to or below 35 mg/dL (1.9 mmol/L). In addition to stopping the test, sweetened orange juice or cola should be given by mouth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If hypoglycemic symptoms are severe, administration of 25 g of 50 percent glucose should be administered intravenously (see
         <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">
          "Hypoglycemia in adults with diabetes mellitus", section on 'With IV access'
         </a>
         ). The solution should be infused over a period of one minute (slowly, because of its hypertonicity) if seizure, chest pain, confusion, disorientation, or other potentially serious complications occur; this will result in hyperglycemia within 30 seconds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood should be drawn for measurement of cortisol when glucose is given and 15 minutes later as levels continue to increase despite increasing serum glucose concentrations [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Normal reference values
         </span>
         <span class="headingEndMark">
          —
         </span>
         The criteria for a normal serum cortisol response in individuals without adrenal insufficiency ranged from 18 to approximately 22 mcg/dL (500 to 600 nmol/L) in multiple studies using different assays and various methods. The newer, more specific cortisol immunoassays and tandem mass spectrometry (LC-MS/MS) methods may give significantly lower cortisol results (as much as 25 percent lower) [
         <a href="#rid14">
          14
         </a>
         ]. Because of this, serum cortisol cutoffs for any stimulation test must be individualized to the method used in the clinical laboratory [
         <a href="#rid15">
          15-18
         </a>
         ]. The highest (peak) serum cortisol is used to interpret the response, rather than the cortisol increment [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults", section on 'ACTH stimulation tests'
         </a>
         .)
        </p>
        <p>
         Plasma ACTH also can be measured. The normal plasma ACTH response has not been carefully defined, but the peak concentration should exceed 150 pg/mL (33 pmol/L) [
         <a href="#rid19">
          19-23
         </a>
         ].
        </p>
        <p>
         There is increasing evidence that the salivary cortisol response to insulin-induced hypoglycemia can provide useful information, although definitive cutoffs have yet to be established [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         An inadequate cortisol response can be due to hypopituitarism of any etiology, including hypothalamic corticotropin-releasing hormone (CRH) deficiency, isolated ACTH deficiency, partial or panhypopituitarism, or hypothalamic-pituitary suppression from use of opioids or synthetic glucocorticoids [
         <a href="#rid1">
          1,27-29
         </a>
         ]; it also can be due to primary adrenal insufficiency when serum cortisol levels rather than plasma ACTH values are used as the endpoints of the test. However, false-negative results in patients who have partial adrenal insufficiency can occur because hypoglycemia is such a potent stimulus that it may obscure a partial defect. (See
         <a class="medical medical_review" href="/z/d/html/173.html" rel="external">
          "Causes of secondary and tertiary adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoglycemia is a stronger stimulus of ACTH secretion than is hypocortisolemia (as induced by
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         ). Consequently, patients may have a normal response to hypoglycemia, but an inadequate response to metyrapone, which can detect subtle defects in ACTH secretion. The reverse is almost never true.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The low-dose (1 mcg) one-hour
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         does not result in maximally stimulating plasma ACTH concentrations. Thus, as with
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         , patients may have a normal serum cortisol response to hypoglycemia (or to the high-dose cosyntropin test), but an inadequate response to low-dose cosyntropin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1084340294">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112295.html" rel="external">
          "Society guideline links: Adrenal insufficiency"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114455.html" rel="external">
          "Society guideline links: Growth hormone deficiency and other growth disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1823921">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical utility
         </strong>
         – Although insulin-induced hypoglycemia is a valid and perhaps the most physiologically rational test of hypothalamic-pituitary-adrenal response to stress, there is little, if any, reason for performing the test in clinical practice except in patients with suspected recent corticotropin (ACTH) deficiency (eg, recent pituitary surgery). (See
         <a class="local">
          'Clinical uses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Practical aspects
         </strong>
         – The test is relatively safe (if a clinician is present) in patients with no history of seizures or cardiovascular or cerebrovascular disease, but otherwise should not be performed. (See
         <a class="local">
          'Practical aspects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Test procedure
         </strong>
         – Insulin (usually at a dose of 0.15 units/kg [in patients with low basal cortisol levels, the dose should be reduced to 0.1 units/kg]) is given with the aim to achieve hypoglycemia of 35 to 45 mg/dL (1.9 to 2.5 mmol/L) or less. (See
         <a class="local">
          'Procedure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cortisol concentrations are measured at 0, 30, and 45 minutes after insulin is given and, when appropriate, 15 minutes after glucose has been given to reduce symptoms of hypoglycemia. It may also be useful to measure the plasma ACTH response. (See
         <a class="local">
          'Normal reference values'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation of results
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adequacy of cortisol response
         </strong>
         – The criteria for a normal serum cortisol response range from 18 to approximately 22 mcg/dL (500 to 600 nmol/L) in studies using different assays and various methods to establish a normal reference range. Newer, more specific cortisol assays have cutoffs approximately 25 percent lower. Failure to reach this level is indicative of an inadequate response
         <strong>
          only
         </strong>
         if the serum glucose decreased to 35 to 45 mg/dL (1.9 to 2.5 mmol/L) or less. If this degree of hypoglycemia was not achieved and the cortisol is inadequate, the test was ended prematurely and must be repeated. It is the peak serum cortisol concentration that is achieved rather than the increment that is important. (See
         <a class="local">
          'Interpretation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Underlying etiology
         </strong>
         – An inadequate cortisol response can be due to hypopituitarism of any etiology, including hypothalamic corticotropin-releasing hormone (CRH) deficiency, isolated ACTH deficiency, partial or panhypopituitarism, or hypothalamic-pituitary suppression from use of opioids or synthetic glucocorticoids; it can also be due to primary adrenal insufficiency. However, false-negative results in patients who have partial adrenal insufficiency can occur because hypoglycemia is such a potent stimulus that it may obscure a partial defect. (See
         <a class="local">
          'Interpretation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1101378492">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes 2010; 17:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Sharma ST, Nieman LK. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol 2014; 4:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dökmetaş HS, Colak R, Keleştimur F, et al. A comparison between the 1-microg adrenocorticotropin (ACTH) test, the short ACTH (250 microg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery. J Clin Endocrinol Metab 2000; 85:3713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courtney CH, McAllister AS, McCance DR, et al. The insulin hypoglycaemia and overnight metyrapone tests in the assessment of the hypothalamic-pituitary-adrenal axis following pituitary surgery. Clin Endocrinol (Oxf) 2000; 53:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klose M, Lange M, Kosteljanetz M, et al. Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test. Clin Endocrinol (Oxf) 2005; 63:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           English K, Inder WJ, Weedon Z, et al. Prospective evaluation of a week one overnight metyrapone test with subsequent dynamic assessments of hypothalamic-pituitary-adrenal axis function after pituitary surgery. Clin Endocrinol (Oxf) 2017; 87:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg C, Meinel T, Lahner H, et al. Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. Eur J Endocrinol 2010; 162:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agha A, Tomlinson JW, Clark PM, et al. The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 2006; 91:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maghnie M, Uga E, Temporini F, et al. Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol 2005; 152:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Sun S, Jia H, et al. The Optimized Calculation Method for Insulin Dosage in an Insulin Tolerance Test (ITT): A Randomized Parallel Control Study. Front Endocrinol (Lausanne) 2020; 11:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long TD, Ellingrod VL, Kathol RG, et al. Lack of menstrual cycle effects on hypothalamic-pituitary-adrenal axis response to insulin-induced hypoglycaemia. Clin Endocrinol (Oxf) 2000; 52:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simsek Y, Karaca Z, Tanriverdi F, et al. A comparison of low-dose ACTH, glucagon stimulation and insulin tolerance test in patients with pituitary disorders. Clin Endocrinol (Oxf) 2015; 82:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab 1998; 83:2350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javorsky BR, Raff H, Carroll TB, et al. New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays. J Endocr Soc 2021; 5:bvab022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raverot V, Richet C, Morel Y, et al. Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys® Cortisol II assay. Ann Endocrinol (Paris) 2016; 77:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kline GA, Buse J, Krause RD. Clinical implications for biochemical diagnostic thresholds of adrenal sufficiency using a highly specific cortisol immunoassay. Clin Biochem 2017; 50:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueland GÅ, Methlie P, Øksnes M, et al. The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS. J Clin Endocrinol Metab 2018; 103:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Farhan N, Pickett A, Ducroq D, et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf) 2013; 78:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staub JJ, Jenkins JS, Ratcliffe JG, Landon J. Comparison of corticotrophin and corticosteroid response to lysine vasopressin, insulin, and pyrogen in man. Br Med J 1973; 1:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleisher MR, Glass D, Bitensky L, et al. Plasma corticotrophin levels during insulin-hypoglycaemia: comparison of radioimmunoassay and cytochemical bioassay. Clin Endocrinol (Oxf) 1974; 3:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donald RA. Plasma immunoreactive corticotrophin and cortisol response to insulin hypoglycemia in normal subjects and patients with pituitary disease. J Clin Endocrinol Metab 1971; 32:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krieger DT, Liotta AS, Suda T, et al. Human plasma immunoreactive lipotropin and adrenocorticotropin in normal subjects and in patients with pituitary-adrenal disease. J Clin Endocrinol Metab 1979; 48:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeCherney GS, DeBold CR, Jackson RV, et al. Effect of ovine corticotropin-releasing hormone administered during insulin-induced hypoglycemia on plasma adrenocorticotropin and cortisol. J Clin Endocrinol Metab 1987; 64:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perogamvros I, Owen LJ, Keevil BG, et al. Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing. Clin Endocrinol (Oxf) 2010; 72:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. Eur J Endocrinol 2009; 160:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karpman MS, Neculau M, Dias VC, Kline GA. Defining adrenal status with salivary cortisol by gold-standard insulin hypoglycemia. Clin Biochem 2013; 46:1442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ 2021; 374:n1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries F, Bruin M, Lobatto DJ, et al. Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadelha MR, Karavitaki N, Fudin J, et al. Opioids and pituitary function: expert opinion. Pituitary 2022; 25:52.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 164 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20375886" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Adrenal insufficiency: etiology, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24715566" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11061529" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A comparison between the 1-microg adrenocorticotropin (ACTH) test, the short ACTH (250 microg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10971447" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The insulin hypoglycaemia and overnight metyrapone tests in the assessment of the hypothalamic-pituitary-adrenal axis following pituitary surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16268800" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28815741" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prospective evaluation of a week one overnight metyrapone test with subsequent dynamic assessments of hypothalamic-pituitary-adrenal axis function after pituitary surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20207728" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16249286" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15879359" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32328036" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The Optimized Calculation Method for Insulin Dosage in an Insulin Tolerance Test (ITT): A Randomized Parallel Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10848884" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lack of menstrual cycle effects on hypothalamic-pituitary-adrenal axis response to insulin-induced hypoglycaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24953859" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A comparison of low-dose ACTH, glucagon stimulation and insulin tolerance test in patients with pituitary disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9661607" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33768189" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27449530" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys®Cortisol II assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28192125" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical implications for biochemical diagnostic thresholds of adrenal sufficiency using a highly specific cortisol immunoassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29452421" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22994849" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4346579" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of corticotrophin and corticosteroid response to lysine vasopressin, insulin, and pyrogen in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4365966" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Plasma corticotrophin levels during insulin-hypoglycaemia: comparison of radioimmunoassay and cytochemical bioassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4321504" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Plasma immunoreactive corticotrophin and cortisol response to insulin hypoglycemia in normal subjects and patients with pituitary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/219000" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Human plasma immunoreactive lipotropin and adrenocorticotropin in normal subjects and in patients with pituitary-adrenal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3033009" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of ovine corticotropin-releasing hormone administered during insulin-induced hypoglycemia on plasma adrenocorticotropin and cortisol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19302583" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18952762" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684774" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Defining adrenal status with salivary cortisol by gold-standard insulin hypoglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34253540" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Glucocorticoid induced adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31511863" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35066756" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Opioids and pituitary function: expert opinion.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
